Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Jun 5, 2023
Date Accepted: Dec 11, 2024
Good quality mHealth apps for endometriosis care: Systematic search
ABSTRACT
Background:
Mobile health applications (m-health apps) are being increasingly used for endometriosis care by the endometriosis community and clinicians. Critical evaluation is needed to inform users of their quality.
Objective:
To identify the best quality m-health apps for endometriosis care.
Methods:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines were followed to conduct a Google Play and Apple App store search using the terms ‘endometriosis, adenomyosis and pelvic pain’ on 24th July 2020. M-health apps that were free, in the English language and related to endometriosis, adenomyosis, or pelvic pain were included. ENLIGHT quality assessment criteria were used for quality assessment. M-health apps that scored an overall average of > 4 or more, were considered high-quality.
Results:
Five m-health apps (Endo App, Essential Pain Management, Pathways The Pain Relief App, QENDO and Symptomate) scored > 4 or more indicating high-quality apps. Endo App and Essential Pain Management are useful resources in clinical practice, while the others are designed for use by members of the endometriosis community.
Conclusions:
We identified good quality m-health apps for endometriosis that will best serve the endometriosis community and clinicians. We also provide suggestions for development of endometriosis m-health apps to researchers and developers.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.